Based on a previously comprehensive study, the VGH-TAYLOR trial, we elucidate the genomic alterations of HER2-low tumors from the updated 648 samples of Taiwanese breast cancer patients undergoing targeted sequencing [7,8]. This evidence concerns the gene ERBB2 and breast cancer.